Halozyme(US:HALO)2024-10-31 23:26Financial Performance - Third quarter total revenue reached $290 million, a 34% increase year-over-year[5,21] - Royalty revenue increased by 36% to $155 million in the third quarter[5,21] - Adjusted EBITDA for the third quarter was $184 million, a 60% increase year-over-year[5,21] - Non-GAAP diluted EPS increased by 69% to $127[5,21] Guidance and Outlook - The company raised its 2024 total revenue guidance to $970 million - $1020 million, representing a 17-23% year-over-year growth[6] - 2024 royalty revenue guidance was raised to $550 million - $565 million, a 23-26% year-over-year increase[6] - Adjusted EBITDA guidance for 2024 was raised to $595 million - $625 million, a 40-47% year-over-year increase[6] - Non-GAAP diluted EPS guidance for 2024 was raised to $400 - $420, a 44-52% year-over-year increase[6] Growth Drivers - Darzalex SC sales increased 23% to $3 billion in 3Q 2024[8] - Phesgo sales YTD 2024 reached CHF 12 billion, with a growth of 58% CER[12]